Verrica Pharmaceuticals IncNASDAQ:VRCA
- LAST PRICE9.0500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.6200/ 2
- Ask / Lots12.5000/ 1
- Open / Previous Close0.0000 / 9.0500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRCA |
|---|---|---|
| 09:32 ET | 1829 | 8.86 |
| 09:34 ET | 1443 | 8.87 |
| 09:39 ET | 1400 | 9.07 |
| 09:41 ET | 1367 | 9.04 |
| 09:43 ET | 100 | 9.08 |
| 09:52 ET | 205 | 9.12 |
| 09:54 ET | 1084 | 9.195 |
| 09:56 ET | 2222 | 9.245 |
| 09:57 ET | 100 | 9.23 |
| 09:59 ET | 300 | 9.245 |
| 10:03 ET | 100 | 9.275 |
| 10:08 ET | 109 | 9.2794 |
| 10:10 ET | 100 | 9.28 |
| 10:14 ET | 100 | 9.28 |
| 10:15 ET | 1350 | 9.305 |
| 10:17 ET | 100 | 9.355 |
| 10:32 ET | 813 | 9.3 |
| 10:33 ET | 200 | 9.34 |
| 10:35 ET | 498 | 9.33 |
| 10:37 ET | 100 | 9.395 |
| 10:39 ET | 900 | 9.27 |
| 10:42 ET | 100 | 9.26 |
| 10:46 ET | 100 | 9.27 |
| 10:51 ET | 100 | 9.27 |
| 11:02 ET | 200 | 9.27 |
| 11:11 ET | 1600 | 9.205 |
| 11:15 ET | 1300 | 9.16 |
| 11:22 ET | 100 | 9.1 |
| 11:26 ET | 300 | 9.155 |
| 11:27 ET | 100 | 9.155 |
| 11:33 ET | 400 | 9.2 |
| 11:36 ET | 425 | 9.18 |
| 11:38 ET | 100 | 9.18 |
| 11:44 ET | 4800 | 9.29 |
| 11:45 ET | 2062 | 9.26 |
| 11:51 ET | 200 | 9.18 |
| 11:56 ET | 600 | 9.17 |
| 12:03 ET | 100 | 9.21 |
| 12:05 ET | 100 | 9.18 |
| 12:12 ET | 100 | 9.19 |
| 12:20 ET | 1041 | 9.26 |
| 12:23 ET | 866 | 9.29 |
| 12:30 ET | 100 | 9.28 |
| 12:32 ET | 600 | 9.35 |
| 12:34 ET | 328 | 9.315 |
| 12:36 ET | 100 | 9.315 |
| 12:38 ET | 100 | 9.315 |
| 12:48 ET | 2021 | 9.3 |
| 12:54 ET | 557 | 9.3 |
| 12:56 ET | 400 | 9.29 |
| 12:59 ET | 200 | 9.3 |
| 01:06 ET | 269 | 9.28 |
| 01:08 ET | 100 | 9.3 |
| 01:10 ET | 100 | 9.28 |
| 01:15 ET | 300 | 9.2701 |
| 01:17 ET | 200 | 9.25 |
| 01:21 ET | 959 | 9.2 |
| 01:24 ET | 2077 | 9.18 |
| 01:28 ET | 6322 | 9.2 |
| 01:30 ET | 100 | 9.18 |
| 01:32 ET | 100 | 9.18 |
| 01:33 ET | 866 | 9.19 |
| 01:35 ET | 100 | 9.16 |
| 01:37 ET | 310 | 9.13 |
| 01:39 ET | 600 | 9.09 |
| 01:42 ET | 2279 | 9.1 |
| 01:44 ET | 100 | 9.135 |
| 01:46 ET | 100 | 9.1 |
| 01:48 ET | 100 | 9.12 |
| 01:50 ET | 300 | 9.11 |
| 01:53 ET | 2200 | 9.08 |
| 01:55 ET | 300 | 9.14 |
| 02:00 ET | 200 | 9.11 |
| 02:04 ET | 1000 | 9.12 |
| 02:06 ET | 800 | 9.13 |
| 02:08 ET | 200 | 9.13 |
| 02:15 ET | 800 | 9.13 |
| 02:20 ET | 100 | 9.095 |
| 02:22 ET | 2074 | 9.13 |
| 02:24 ET | 400 | 9.1 |
| 02:26 ET | 500 | 9.08 |
| 02:27 ET | 200 | 9.08 |
| 02:33 ET | 200 | 9.04 |
| 02:36 ET | 500 | 9.055 |
| 02:38 ET | 250 | 9.04 |
| 02:42 ET | 100 | 9.065 |
| 02:44 ET | 2611 | 9.09 |
| 02:45 ET | 2441 | 9.03 |
| 02:47 ET | 100 | 9.04 |
| 02:51 ET | 1110 | 9 |
| 02:54 ET | 200 | 9 |
| 02:56 ET | 100 | 9 |
| 02:58 ET | 100 | 9.02 |
| 03:00 ET | 503 | 9.025 |
| 03:02 ET | 600 | 9.02 |
| 03:03 ET | 400 | 9.0299 |
| 03:05 ET | 100 | 9 |
| 03:07 ET | 200 | 9 |
| 03:12 ET | 100 | 9 |
| 03:16 ET | 400 | 9 |
| 03:20 ET | 200 | 9 |
| 03:21 ET | 1644 | 9.0399 |
| 03:23 ET | 800 | 9.015 |
| 03:25 ET | 2943 | 9 |
| 03:27 ET | 300 | 9.02 |
| 03:30 ET | 500 | 9.02 |
| 03:32 ET | 384 | 9.025 |
| 03:34 ET | 1337 | 9.11 |
| 03:36 ET | 1237 | 9.125 |
| 03:38 ET | 724 | 9.16 |
| 03:39 ET | 400 | 9.2 |
| 03:41 ET | 800 | 9.21 |
| 03:43 ET | 3200 | 9.14 |
| 03:45 ET | 100 | 9.1 |
| 03:48 ET | 600 | 9.115 |
| 03:50 ET | 309 | 9.12 |
| 03:52 ET | 2625 | 9.12 |
| 03:54 ET | 300 | 9.115 |
| 03:56 ET | 3856 | 9.04 |
| 03:57 ET | 1300 | 9.05 |
| 03:59 ET | 11520 | 9.05 |
May 17, 2024
May 16, 2024
DJ Verrica Pharmaceuticals Price Target Maintained With a $16.00/Share by Needham, from 11:51AM ET on Thursday May 16, 2024 by Dow Jones
11:51AM ET on Thursday May 16, 2024 by Dow Jones
May 15, 2024
Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH(R) for the Treatment of Common Warts, from 7:30AM ET on Wednesday May 15, 2024 by Dow Jones
7:30AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
DJ Verrica Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 7:11AM ET on Tuesday May 14, 2024 by Dow Jones
7:11AM ET on Tuesday May 14, 2024 by Dow JonesDJ Verrica Pharmaceuticals Is Maintained at Buy by Needham, from 5:51AM ET on Tuesday May 14, 2024 by Dow Jones
5:51AM ET on Tuesday May 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verrica Pharmaceuticals Inc | 383.9M | -5.2x | --- |
Precigen Inc | 348.3M | -3.5x | --- |
Jasper Therapeutics Inc | 359.3M | -4.3x | --- |
ASP Isotopes Inc | 263.5M | -9.5x | --- |
Telomir Pharmaceuticals Inc | 165.8M | -8.1x | --- |
China Health Industries Holdings Inc | 125.8M | -83.4x | --- |
Company Information
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Contact Information
- Headquarters
- 10 N High St Ste 200WEST CHESTER, PA, United States 19380-3014
- Phone
- 484-453-3300
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Ted White
- Chief Financial Officer
- P. Terence Kohler
- General Counsel, Company Secretary, Chief Legal Office
- Christopher Hayes
- Chief Commercial Officer
- Joe Bonaccorso
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $383.9M |
|---|---|
Revenue (TTM) | $8.9M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.79 |
EPS | $-1.75 |
Book Value | $0.47 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | 43.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -866.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
